Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population-Reference-Cited by-同舟云学术

Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population

Published:2021-06-28 Issue:4 Volume:28 Page:405-416
ISSN:1120-9879
Container-title:High Blood Pressure & Cardiovascular Prevention
language:en
Short-container-title:High Blood Press Cardiovasc Prev

Author:

Sattar Yasar,Mukuntharaj Pradeeksha,Zghouzi Mohamed,Suleiman Abdul-Rahman M.,Attique Hassan,Ullah Waqas,Sana Muhammad Khawar,Zaher Nathan,Mehmood Maham,Doshi Rajkumar P.,Panchal Ankur,Mir Tanveer,Nadeem Muhammad,Ali Omar E.,Mohamed Mohamad,Bagur Rodrigo,Elgendy Islam Y.,Mamas Mamas A.,Alraies M. Chadi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40292-021-00462-w.pdf

Reference78 articles.

1. COVID-19 Map—Johns Hopkins Coronavirus Resource Center [Internet]. Johns Hopkins Coronavirus Resource Center.: https://coronavirus.jhu.edu/map.html.

2. Sattar Y, Ullah W, Rauf H, Virk HUH, Yadav S, Chowdhury M, Connerney M, Mamtani S, Pahuja M, Patel RD, Mir T, Almas T, Moussa Pacha H, Chadi Alraies M. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. Int J Cardiol Heart Vasc. 2020;29:100589. https://doi.org/10.1016/j.ijcha.2020.100589. PMID: 32724831; PMCID: PMC7359794.

3. Oudit G, Kassiri Z, Jiang C, Liu P, Poutanen S, Penninger J, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618–25.

4. Negreira-Caamaño M, Piqueras-Flores J, Martínez-DelRio J, Nieto-Sandoval-Martin-DeLaSierra P, Aguila-Gordo D, Mateo-Gomez C, Salas-Bravo D, Rodriguez-Martinez M, Negreira-Caamaño M. Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19. High Blood Press Cardiovasc Prev. 2020;27(6):561–568.

5. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reinventing the renin–angiotensin–aldosterone system based on experience from the COVID‐19 pandemic;The Journal of Physiology;2024-08-28

2. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway;Cureus;2024-03-05

3. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity;Revista Portuguesa de Cardiologia;2023-04

4. Proton Pump Inhibitors in the COVID-19 Pandemic;The Russian Archives of Internal Medicine;2022-07-29

5. The effects of antihypertensive medications on severity and outcomes of COVID19;Journal of Human Hypertension;2022-07-09